The 2026 AHA/ASA guidelines for acute ischemic stroke (AIS) introduce updated recommendations across prehospital stroke care, intravenous thrombolysis, endovascular thrombectomy, and post-reperfusion management. The recommendations reflect recent clinical evidence on treatment eligibility, therapeutic approaches, and strategies to improve functional outcomes in adults and selected pediatric patients.
For cardiologists and other physicians involved in cardiovascular and cerebrovascular care, understanding these updates is essential to recognizing changes in acute stroke management and the evidence supporting current treatment recommendations.
This article summarizes the key take-home messages from the 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke, developed by the American Heart Association and the American Stroke Association (AHA/ASA).
Prehospital stroke care: Mobile stroke units and hospital destination
Mobile stroke units enable earlier treatment
Mobile stroke units (MSUs) enable rapid identification and treatment of patients with acute ischemic stroke who are eligible for thrombolysis. Recent studies have highlighted their benefits compared with conventional emergency medical services.
Based on evidence supporting their safety and benefit, the 2026 guidelines now include recommendations related to MSU implementation when these units are available.
Selecting the appropriate hospital for suspected stroke
Identifying the appropriate transport destination for patients with suspected stroke remains challenging in the prehospital setting. Previous guidelines recommended transport to the nearest thrombolytic-capable facility. However, recent evidence supports considering the characteristics of the local stroke care system. In the absence of well-functioning systems with rapid interhospital transfer processes, the guidelines endorse considering direct transport to the closest hospital capable of performing endovascular thrombectomy (EVT).
Intravenous thrombolysis: Updated treatment recommendations
Intravenous thrombolysis (IVT) remains a mainstay of medical management for patients with acute ischemic stroke. The 2026 guidelines update recommendations on thrombolytic agents, treatment timing, imaging selection, and patient eligibility.
Alteplase or tenecteplase within the 4.5-hour treatment window
Numerous international trials have demonstrated the noninferiority of intravenous tenecteplase compared with alteplase, with potential advantages associated with tenecteplase. Consequently, the 2026 guidelines endorse the use of either alteplase or tenecteplase for eligible patients within the 4.5-hour thrombolytic treatment window.
Rapid thrombolysis for eligible patients with disabling deficits
The guidelines emphasize rapid thrombolytic treatment in eligible patients presenting with disabling neurological deficits within the 4.5-hour window, regardless of their National Institutes of Health Stroke Scale (NIHSS) score. For these patients, treatment should not be delayed for advanced imaging selection.
Extended-window thrombolysis for selected patients
The updated recommendations also support extended-window thrombolysis for selected patients with stroke of unknown onset or those presenting 4.5–9 hours after symptom onset. Eligibility is based on advanced imaging criteria, including diffusion-weighted imaging–fluid-attenuated inversion recovery (DWI-FLAIR) mismatch or perfusion-based mismatch.
Non-disabling neurological deficits: dual antiplatelet therapy preferred
For patients presenting within the 4.5-hour window with non-disabling deficits, such as an isolated sensory syndrome, trials have failed to demonstrate a benefit from thrombolysis. In this population, dual antiplatelet therapy is preferred and recommended.
Adjunctive antithrombotic therapy is not recommended to enhance thrombolysis
New studies have evaluated adjunctive antithrombotic therapy, including argatroban and eptifibatide, administered concurrently with intravenous thrombolysis (IVT). These studies have shown no benefit. Therefore, adjunctive antithrombotic drugs are not recommended to enhance outcomes from thrombolytic therapy.
Endovascular thrombectomy: expanded treatment eligibility
Endovascular thrombectomy (EVT) is an established standard treatment for patients with acute ischemic stroke caused by large vessel occlusion (LVO), supported by numerous randomized controlled trials. Recent evidence supports expanding EVT to patient populations previously considered ineligible, including selected patients with larger ischemic cores identified through diagnostic imaging.
EVT for large ischemic core stroke
Several studies indicate that endovascular thrombectomy (EVT) benefits some patients with larger ischemic core strokes. These findings support broader consideration of endovascular treatment in appropriately selected patients based on diagnostic imaging.
Basilar artery occlusion: strong recommendation for EVT
The 2026 guidelines provide a strong recommendation for EVT in patients with basilar artery occlusion who present within 24 hours of symptom onset and have an NIHSS score of ≥10. Several trials have demonstrated improved functional outcomes with EVT compared with medical management alone in this population.
Endovascular treatment in pediatric acute ischemic stroke
The 2026 guidelines introduce, for the first time, recommendations on interventional treatment for pediatric patients with acute ischemic stroke (AIS). Although further work is needed to adapt prehospital and hospital stroke protocols for children, expert consensus and recent studies highlight the importance of early stroke recognition in pediatric patients.
Recent evidence supports the safety and potential benefits of endovascular treatment in selected pediatric patients with acute ischemic stroke. These recommendations establish a foundation for future guidance and address key phases of acute stroke care in children.
Post-stroke management: glycemic control and blood pressure
The 2026 acute ischemic stroke guidelines update glycemic management in acute ischemic stroke and blood pressure management after reperfusion therapy. Recent trials provide evidence against certain intensive management strategies intended to improve functional outcomes.
Intensive glucose control does not improve clinical outcomes
The recommendations for glycemic management have changed since the previous guidelines. Intensive glucose control targeting 80–130 mg/dL is not recommended to improve clinical outcomes in patients with acute ischemic stroke. This approach also increases the risk of severe hypoglycemia.
Intensive blood pressure reduction after IVT and EVT is not recommended
Several new trials have assessed the efficacy and safety of lowering blood pressure (BP)Â after intravenous thrombolysis and endovascular thrombectomy in adults. The findings indicate that more intensive BP reduction does not improve functional outcomes after IVT and may cause harm after EVT.
Accordingly, intensive systolic BP lowering to below 140 mm Hg is not recommended, even in the setting of complete reperfusion, such as thrombolysis in cerebral infarction (TICI) grade 3 flow.
Translating the 2026 stroke guidelines into clinical practice
The 2026 AHA/ASA acute ischemic stroke guidelines update recommendations across the stroke care pathway, from prehospital recognition and transport to reperfusion treatment and subsequent physiological management.
For clinicians involved in acute stroke care, these recommendations underscore the importance of timely treatment, appropriate patient selection, and evidence-based management strategies aimed at improving functional outcomes.
Heart rhythm monitoring after stroke
The role of holter monitoring in detecting atrial fibrillation
Ambulatory ECG holter monitoring after a cryptogenic stroke or transient ischemic attack (TIA) is an important strategy for identifying paroxysmal atrial fibrillation (AF) that may go undetected during the initial evaluation. The EMBRACE randomized clinical trial found that, among patients aged 55 years or older with a recent cryptogenic stroke or TIA, 30-day noninvasive ambulatory ECG monitoring detected atrial fibrillation (AF) in 16.1% of patients, compared with 3.2% with conventional 24-hour monitoring—more than a fivefold difference. Anticoagulant prescribing was also higher with prolonged monitoring (18.6% vs. 11.1%), supporting its use to detect previously unrecognized AF and inform secondary stroke-prevention decisions, although the trial did not establish that monitoring itself reduces recurrent stroke.
medilog® AR Holter System: Supporting post-stroke rhythm monitoring
The medilog® AR Holter System by SCHILLER supports ambulatory ECG monitoring in the evaluation of patients after stroke, helping clinicians investigate potential episodes of atrial fibrillation that may influence secondary prevention strategies. Explore its advanced diagnostic capabilities designed to support the detection of atrial fibrillation in clinical practice:
- Flexible recording options: A dual-battery concept supports 24- and 72-hour recordings, as well as continuous recording for up to 14 days using a single AAA battery.
- Built for clinical use: A robust, easy-to-clean recorder with shock and splash resistance.
- Easy patient setup: Designed for straightforward setup in both adult and pediatric patients.
- Time-saving analysis software: Automatic analysis helps streamline ECG review and final report generation.
- Fast data transfer: Transfer a 24-hour Holter study in approximately 90 seconds.
- Efficient arrhythmia review: Automatically classifies and groups key heartbeat types and arrhythmic events for clinician review.
- Customizable reporting: Configurable analysis and reporting functions to suit clinical requirements.
See the medilog® AR Holter System in action. Request a personalized demonstration to explore its advanced ECG monitoring features and discover how SCHILLER can support your clinical workflow and post-stroke patient evaluation.
FAQ About the 2026 AHA/ASA Guidelines for acute ischemic stroke
What does the 2026 AHA/ASA guideline recommend for the treatment of acute ischemic stroke?
The 2026 guideline from the American Heart Association/American Stroke Association (AHA/ASA) updates recommendations for the early management of acute ischemic stroke (AIS). It covers prehospital care, initial evaluation, reperfusion therapies, early in-hospital management of complications, and the initiation of secondary prevention measures.
What are the main reperfusion options for acute ischemic stroke according to the 2026 AHA/ASA guideline?
The main reperfusion strategies are intravenous thrombolysis (IVT) and endovascular thrombectomy (EVT). Treatment selection depends on the time since symptom onset, the severity of the neurological deficit, the presence of a large-vessel occlusion (LVO), neuroimaging findings, and other eligibility criteria. In selected patients, both strategies may be used sequentially.
Which medications does the 2026 AHA/ASA guideline consider for intravenous thrombolysis?
For eligible patients treated within 4.5 hours of symptom onset, the guideline considers alteplase and tenecteplase as options for intravenous thrombolysis. The choice of agent should be based on the clinical context, availability, neuroimaging findings, and specific eligibility criteria.
What role does neuroimaging play in the early diagnosis and treatment of acute ischemic stroke?
Neuroimaging is essential for excluding intracranial hemorrhage, confirming suspected ischemic stroke, identifying arterial occlusions, and assessing the extent of ischemic tissue. Computed tomography or magnetic resonance imaging, together with vascular imaging and, in selected patients, perfusion imaging or a diffusion-weighted imaging–fluid-attenuated inversion recovery (DWI-FLAIR) mismatch, guides eligibility for IVT and EVT.
What aspects of post-stroke care does the 2026 AHA/ASA guideline address?
The guideline addresses early in-hospital management after reperfusion, including blood pressure and glucose control, the prevention and detection of complications, and the initiation of secondary prevention measures. Swallowing assessment, nutritional support, and rehabilitation are components of comprehensive stroke care and should be provided according to established stroke-care protocols.